Divi’s Laboratories reported a healthy set of earnings for the fourth quarter of FY26, supported by steady revenue growth and improved profitability on a year-on-year basis. The company also announced a final dividend of ₹30 per share for the financial year 2025-26.
Divi’s Laboratories Q4 FY26 Results
Divi’s Laboratories posted a consolidated net profit of ₹751 crore in Q4 FY26, registering a growth of 13.4% compared to ₹662 crore reported in the corresponding quarter last year.
The company’s revenue from operations rose 9.5% year-on-year to ₹2,831 crore against ₹2,585 crore in Q4 FY25, supported by stable demand across its pharmaceutical and custom synthesis business segments.
EBITDA for the quarter increased 5.4% to ₹934 crore, compared to ₹886 crore in the year-ago period. However, EBITDA margin declined to 33% from 34.3% on a YoY basis, indicating some pressure on operating profitability.
Dividend Announcement
The board of Divi’s Laboratories has recommended a final dividend of ₹30 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
The quarterly numbers reflect stable operational performance for Divi’s Laboratories despite a slight contraction in margins during the quarter. Market participants will closely watch management commentary on export demand, custom synthesis growth, and margin outlook going forward.